Clinical data | |
---|---|
Pronunciation | tis" a jen" lek loo' se /ˌtɪsədʒen'leklusel/ |
Trade names | Kymriah |
Other names | CTL019, CART-19 |
AHFS/Drugs.com | Professional Drug Facts |
MedlinePlus | a617053 |
License data | |
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 16.8 days |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG |
Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer (adoptive cell transfer).[10][7]
T cells from a person with cancer are removed, genetically engineered to make a specific chimeric cell surface receptor with components from both a T-cell receptor and an antibody specific to a protein on the cancer cell, and transferred back to the person. The T cells are engineered to target a protein called CD19 that is common on B cells. A chimeric T cell receptor ("CAR-T") is expressed on the surface of the T cell.[medical citation needed]
It was invented and initially developed at the University of Pennsylvania; Novartis completed development, obtained FDA approval, and markets the treatment.[11] In August 2017, it became the first FDA-approved treatment that included a gene therapy step in the United States.[10]
Kymriah EPAR
was invoked but never defined (see the help page).